Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNP-ACTH (1-39) Gel vs Rituximab in Primary Membranous Nephropathy
NCT05696613Phase 3Recruiting
- Sponsor
- Cerium Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Apr 2027
- Modality
- Modified Peptides, Native Peptides
- Countries
- 3
01
Overview
A Phase 3 trial of corticotropin in primary membranous nephropathy (PMN), sponsored by Cerium Pharmaceuticals. Started Mar 2023; status: recruiting.
02
Drugs
corticotropin
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05696613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696613.